Skip to main content
Retour
URGN logo

UroGen Pharma Ltd.

Qualité des données : 100%
URGN
NASDAQ Healthcare Biotechnology
17,66 €
▲ 0,36 € (2,08%)
Cap. Boursière : 859,73M
Fourchette du Jour
16,70 € 17,77 €
Fourchette 52 Semaines
3,42 € 30,00 €
Volume
723 762
Moyenne 50J / 200J
20,20 € / 19,19 €
Clôture Précédente
17,30 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -5,6 0,3
P/B 2,9
ROE % 3,7
Net Margin % -139,8 3,8
Rev Growth 5Y % 23,0 10,0
D/E 0,2

Objectif de Cours des Analystes

Hold
35,60 € +101.6%
Low: 16,00 € High: 60,00 €
BPA Prévisionnel
-1,17 €
CA Est.
240 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 6,62 €
5,56 € – 8,21 €
1 B 1
FY2029 4,96 €
4,16 € – 6,15 €
780 M 1
FY2028 2,17 €
0,02 € – 3,03 €
550 M 5

Points Clés

Revenue grew 22,95% annually over 5 years — strong growth
Negative free cash flow of -162,73M
Capital efficient — spends only 0,26% of revenue on capex

Croissance

Revenue Growth (5Y)
22,95%
Revenue (1Y)21,45%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC-409,69%
Net Margin-139,81%
Op. Margin-113,73%

Sécurité

Debt / Equity
N/A
Current Ratio4,01
Interest Coverage-3,69

Valorisation

P/E Ratio
-5,60
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 21,45% Revenue Growth (3Y) 15,21%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 22,95% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 109,79M Net Income (TTM) -153,49M
ROE N/A ROA -76,57%
Gross Margin 88,66% Operating Margin -113,73%
Net Margin -139,81% Free Cash Flow (TTM) -162,73M
ROIC -409,69% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,01
Interest Coverage -3,69 Dividend Yield 0,00%
Valuation
P/E Ratio -5,60 P/B Ratio N/A
P/S Ratio 7,83 PEG Ratio -0,94
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 859,73M Enterprise Value 877,32M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 109,79M 90,40M 82,71M 64,36M 48,04M
Net Income -153,49M -126,87M -102,24M -109,78M -110,82M
EPS (Diluted) -3,19 -2,96 -3,55 -4,79 -4,96
Gross Profit 97,34M 81,52M 73,35M 56,70M 42,89M
Operating Income -124,86M -96,78M -65,54M -79,04M -92,29M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 200,46M 285,71M 178,31M 135,62M 119,75M
Total Liabilities 305,93M 294,51M 243,52M 224,98M 111,33M
Shareholders' Equity -105,47M -8,80M -65,21M -89,36M 8,41M
Total Debt 128,33M 123,39M 99,40M 99,12M 398 000,0
Cash & Equivalents 110,75M 171,99M 95,00M 55,41M 44,36M
Current Assets 186,02M 276,14M 169,19M 128,91M 114,39M
Current Liabilities 46,42M 45,95M 31,21M 23,92M 22,38M